<SUBMISSION>
<ACCESSION-NUMBER>0001144204-05-002434
<TYPE>6-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20050126
<FILING-DATE>20050127
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>pSivida LTD
<CIK>0001314102
<ASSIGNED-SIC>8880
<IRS-NUMBER>000000000
<STATE-OF-INCORPORATION>C3
<FISCAL-YEAR-END>0630
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>6-K
<ACT>34
<FILE-NUMBER>000-51122
<FILM-NUMBER>05551495
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
<PHONE>61 8 9226 5099
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form8k.htm
<TEXT>
<HTML><HEAD>
<TITLE>
Unassociated Document
</TITLE>
</HEAD>
<BODY><DIV><BR>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman, serif"><STRONG>SECURITIES AND EXCHANGE COMMISSION</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif"><STRONG>Washington, D.C. 20549</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman, serif"><STRONG>FORM 6-K</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">REPORT OF FOREIGN ISSUER</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">Pursuant to Rule 13a-16 or 15d-16 of</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">the Securities Exchange Act of 1934</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif"><STRONG>For the month of January 2005</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif"><STRONG>Commission File Number 000-5112</STRONG></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">2</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 16pt; FONT-FAMILY: Times New Roman, serif"><STRONG>pSivida Limited</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">(Translation of registrant&#146;s name into English) </FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">Level 12 BGC Centre</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">28 The Esplanade</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">Perth WA 6000</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">(Address of principal executive offices)</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">(Indicate by check mark whether the registrant files or will file annual reports under cover Form&nbsp;20-F or Form&nbsp;40-F). </FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">Form 20-F </FONT><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</FONT><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F </FONT><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934.</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">Yes </FONT><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</FONT><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No </FONT><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule&nbsp;12g3-2(b): 82- ___. </FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif"><STRONG>SIGNATURE </STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant, pSivida Limited, has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">Date: January 26, 2005</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 207pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">pSivida Limited</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 207pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">By: </FONT><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif"><U>/s/ Aaron Finlay&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 225pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 100.65pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">Aaron Finlay</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 225pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif"><EM>Chief Financial Officer and Company Secretary</EM></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV><BR>
<TABLE id=PGBRK cellSpacing=0 cellPadding=0 width="100%" align=center border=0>

<TR vAlign=top>
<TD width="100%" colSpan=3></TD></TR>
<TR>
<TD align=left width="33%"><FONT size=1>&nbsp;</FONT></TD>
<TD align=middle width="34%"><FONT size=1>&nbsp;</FONT></TD>
<TD align=right width="33%"><FONT size=1>&nbsp;</FONT></TD></TR>
<TR vAlign=top>
<TD width="100%" colSpan=3><FONT size=1>
<HR style="PAGE-BREAK-AFTER: always" color=black noShade SIZE=1>
</FONT></TD></TR></TABLE>
<TABLE id=HDR cellSpacing=0 cellPadding=0 width="100%" align=center border=0>

<TR>
<TD vAlign=bottom width="100%">&nbsp;</TD></TR></TABLE><BR>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif"><STRONG><EM><U>EXHIBIT INDEX</U></EM></STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV align=left>
<TABLE cellSpacing=0 cellPadding=0 width="100%">

<TR>
<TD vAlign=top align=left width="10%">
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif"><STRONG>EXHIBIT 99.1:</STRONG></FONT></DIV></TD>
<TD vAlign=top align=left width="90%">
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">pSivida Limited Press Release, dated January 26, 2005 (pSivida to Commence Trading on NASDAQ on January 27</FONT><FONT style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman, serif"><SUP>th</SUP></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">; Webcast of Investor Meeting to be Broadcast on Internet)</FONT></DIV></TD></TR></TABLE></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left></DIV>
<DIV valign="top"></DIV></DIV></BODY></HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>ex99.htm
<TEXT>
<HTML>
<HEAD>
   <TITLE>ex99</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY bgcolor="#ffffff">


<A name="page_1"></A>

<P>
<IMG src="ex99x1x1.jpg" border=0 width="396" height="121">
</P>
<P align="center">
<B><FONT size=4 face="sans-serif">pSivida to Commence Trading on NASDAQ on January 27th </FONT></B>
</P>
<P align="center">
<B><FONT size=4 face="sans-serif">Webcast of Investor Meeting to be Broadcast on Internet </FONT></B>
</P>
<P>
<FONT size=2 face="sans-serif">Perth, Australia, January 26, 2005 &#150; pSivida Limited (ASX:PSD; Frankfurt:PSI), the global nanotechnology company, today announced that its U.S. securities registration has been declared effective and it has
received preliminary approval from NASDAQ for the listing of its American Depository Shares (ADSs) represented by American Depository Receipts (ADRs) on the NASDAQ National Market.  The Company also announced it has selected Citigroup as its
Depository Bank to administer the ADR program. </FONT>
</P>
<P>
<FONT size=2 face="sans-serif">pSivida expects its ADSs to commence trading on NASDAQ&#146;s National Market today, Thursday, January 27, 2005, under the ticker symbol PSDV. The ADSs will trade on a 10:1 ratio to the company&#146;s ordinary shares
(i.e., 10 pSivida shares for every one ADR). pSivida&#146;s ordinary shares will continue to trade on both the Australian and Frankfurt Stock Exchanges. </FONT>
</P>
<P>
<FONT size=2 face="sans-serif">Gavin Rezos, managing director of pSivida, said, &#147;The NASDAQ listing is an important step forward for pSivida as it looks to achieve success in the world&#146;s largest market in terms of capital and
pharmaceutical products. We are actively seeking to expand our investor base in the U.S. and are pleased to appoint Citigroup as our Depository Bank.&#148; </FONT>
</P>
<P>
<FONT size=2 face="sans-serif">In connection with the listing, pSivida will be hosting an investor meeting on Thursday. Mr. Rezos will discuss pSivida&#146;s use of </FONT><I><FONT size=2 face="sans-serif">BioSilicon&#153;</FONT></I><FONT size=2
face="sans-serif"> to develop innovative methods of controllable drug delivery and diagnostics, the company&#146;s clinical trial timeline, product pipeline and partnerships, and commercial outlook for the future. </FONT>
</P>
<P>
<FONT size=2 face="sans-serif">Those who wish to access the webcast may log onto
<br>
</FONT><U><FONT color="#0000ff" size=2 face="sans-serif">http://www.psivida.com.au/News/Presentations.asp</FONT></U><FONT size=2 face="sans-serif">. The webcast will be
available beginning at 1:00 p.m. Eastern Time. </FONT>
</P>
<P>
<B><FONT size=2 face="sans-serif">About pSivida Ltd. </FONT></B>
</P>
<P>
<FONT size=2 face="sans-serif">pSivida is a global nanotechnology company committed to the biomedical sector and the development of products in healthcare. The company&#146;s focus is the development and commercialization of a modified form of
silicon (porosified or nanostructured silicon) known as BioSilicon&#153;.  As a new and exciting biocompatible and biodegradable</FONT>
</P>

<PAGE>


<A name="page_2"></A>

<P>
<FONT size=2 face="sans-serif">pSivida to Commence Trading on NASDAQ on January 27</FONT><SUP><FONT size=2 face="sans-serif">th</FONT></SUP><FONT size=2 face="sans-serif">
<br>
2 of 3 </FONT>
</P>
<P>
<FONT size=2 face="sans-serif">material, BioSilicon offers multiple potential applications across the high growth healthcare sector, including controlled release drug delivery, targeted cancer therapies (including brachytherapy and localized
chemotherapy), tissue engineering and</FONT>
<FONT size=2 face="sans-serif">orthopedics.  Potential</FONT>
<FONT size=2 face="sans-serif">diagnostics applications</FONT>
<FONT size=2 face="sans-serif">are being</FONT>
<FONT size=2 face="sans-serif">developed through</FONT>
<FONT size=2 face="sans-serif">its</FONT>
<FONT size=2 face="sans-serif">subsidiary AION Diagnostics Limited. pSivida plans to hold a series of information meetings in the U.S. during February and March for investors and potential investors. </FONT>
</P>
<P>
<B><FONT size=2 face="sans-serif">About Citigroup Depository Receipt Services </FONT></B>
</P>
<P>
<FONT size=2 face="sans-serif">Citigroup Depository Receipt Services is a market leader in bringing quality issuers to the U.S. and international markets and promoting Depository Receipts as an effective capital markets tool.  Citibank began
offering ADRs in 1928 and today is widely recognized for providing non-U.S. companies with a gateway to the resources of Citigroup and the means to diversify their shareholder bases and increase liquidity. In addition, Citigroup&#146;s financial
strength and global presence provides clients with access to on-the-ground presence and in-depth knowledge of 90 local markets. </FONT>
</P>
<P>
<FONT size=2 face="sans-serif">For addition information visit </FONT><U><FONT color="#0000ff" size=2 face="sans-serif">www.transactionservices.citigroup.com</FONT></U><FONT size=2 face="sans-serif">. </FONT>
</P>
<P>
<I><FONT size=2 face="sans-serif">A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy
any securities.  You should refer to the company&#146;s registration statement for more complete information concerning the company and its business. The registration statement is available at the SEC&#146;s website: </FONT></I><I><U><FONT
color="#0000ff" size=2 face="sans-serif">www.sec.gov</FONT></U></I><I><FONT size=2 face="sans-serif">. </FONT></I>
</P>
<P>
<I><FONT size=2 face="sans-serif">This document contains forward-looking statements that involve risks and uncertainties including with respect to the commencement of trading of pSivida&#146;s ADSs, the expansion of pSivida&#146;s investor base in
the U.S. and the development and commercialization of BioSilicon. Although the company believes that the expectations reflected in such forward-looking statements are reasonable at this time, they can give no assurance that such expectations will
prove to be correct. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Actual results could differ materially from those anticipated in these forward-looking statements due to many
important factors including:  regulatory issues involving the SEC and/or the NASDAQ Stock Market, including, without limitation the SEC or NASDAQ reopening review of pSivida&#146;s registration statement or listing applications; pSivida&#146;s
failure to take the remaining steps necessary to complete the listing on the NASDAQ National Market, including pSivida&#146;s inability to meet NASDAQ&#146;s initial or continuing listing requirements. In addition, investors may not purchase ADSs on
the market and an active trading market for the ADSs may not develop or be maintained after listing. Further, many important factors could negatively impact pSivida&#146;s business results including: (1) the failure of certain product markets to
develop as expected including due to global economic conditions or alternate remedies being discovered; (2)</FONT></I>
</P>

<PAGE>


<A name="page_3"></A>

<P>
<FONT size=2 face="sans-serif">pSivida to Commence Trading on NASDAQ on January 27</FONT><SUP><FONT size=2 face="sans-serif">th</FONT></SUP><FONT size=2 face="sans-serif">
<br>
3 of 3 </FONT>
</P>
<P>
<I><FONT size=2 face="sans-serif">the company&#146;s failure to complete its current or future clinical trials successfully because of problems with funding, the performance of its product or its partners; (3) the company&#146;s failure to achieve
product approvals on a timely basis, if at all, as a result of regulatory, funding or other issues and (4) the failure of the company&#146;s current and potential products to perform as expected due to unknown factors involving their use. Other
reasons are contained in cautionary statements in the Registration Statement on Form 20-F filed with the U.S. Securities and Exchange Commission, including, without limitation, under item 3.D &#147;Risk Factors&#148; therein. The company does not
undertake to update any oral or written forward-looking statements that may be made by or on behalf of pSivida. </FONT></I>
</P>
<P>
<FONT size=2 face="sans-serif">Contact: </FONT>
</P>
<P>
<FONT size=2 face="sans-serif">In US:</FONT> <br>
<FONT size=2 face="sans-serif">         Beverly Jedynak <br>
President <br>
Martin E. Janis &amp; Company, Inc.     <br>
312-943-1100 ext. 12 <br>
</FONT>
<U><FONT color="#0000ff" size=2 face="sans-serif">bjedynak@janispr.com</FONT></U><FONT size=2 face="sans-serif"> </FONT>
</P>
<P dir="ltr">
<FONT size=2 face="sans-serif">In Australia:    <br>
Joshua Mann     <br>
Investor Relations <br>
PSivida Limited         <br>
+ 61 8 9226 5099        </FONT><U><FONT color="#0000ff" size=2 face="sans-serif">
<br>
joshuamann@psivida.com</FONT></U><FONT size=2 face="sans-serif"> </FONT>
</P>
</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99x1x1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99x1x1.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#`!`+#`X,"A`.#0X2$1`3&"@:&!86
M&#$C)1TH.C,]/#DS.#=`2%Q.0$1713<X4&U15U]B9VAG/DUQ>7!D>%QE9V/_
MVP!#`1$2$A@5&"\:&B]C0CA"8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C
M8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V/_P``1"`!Y`8P#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P"\GC749MS6
MWAJZGC5BHDC=F!P<=0E:>K>)X]-CM8Q9S3W]S&'6TC^\.._&?4=.QKF]`\/:
MCJ-@]Q;:_=649FD`ACW8&&Z\,/Y5JZG>Q:%XS6_U!&%I<VHA6<*6",#D@XY_
M_70!>T7Q2FHWWV"\L9].O2NY8IL_./;(!Z#T]:SV\:7[7-Q':>';FZ2"5HC)
M$[,"0?9#CZ4V35;;Q%XITH:4&F2S+RS3["H4$8QSSV_SS6-:Z/JUY#K%WI6I
MW$#17LH^S1NR"0C!)R#UP?3MUH`[K0]7AUJP^U0H\9#E'C?JC#J#^E1MK.W5
M+ZR\C_CUMQ/OW_>SVQCCZU7\&FP.@QG3R^"Q,WF'+^9_%N]^GX8JG)_R-.M_
M]@]?Y&@"SH/BB+5]/O+J6W^RFU&YT,F[Y=N0V<#K@_E5.V\:&?0+[5&TXH;1
MD'E&;[^X@9SMXZYZ5S;F>UT[3H+?`&LV:6I..C"3&?\`OEL5=U.-8M#\5QH,
M*ES"H'L&6@#I(O$R/X8?6#;,KH2AM]V3OW;0N<?3M523QBR^';754TTR/<3^
M0L"R\YYZ';STZ8[UE>7(OB6+150K;W-S'?DKW`3+`_5EK,D('P_TDF8P#^T.
M95!)3[_S#'/'6@#K-+\2ZG?:A#;3^'+NUCD)#3.6PG&><H/YU5;QI>FYN$M_
M#US<0P2M$TL3LP^4\]$].<9JGX:NK5-:@'_"6W6H,^56WDAE`8D>K$BG^'O$
M>E:.-5@O[GRI6U"5POELV1P.H&.QH`VW\3V[:'!JEK$TJ2RK$49MI4DX.>#T
MJUXAUE=$T\7'DF>1Y%CCB#8+D_@>WM7'A'/A>:[*%(KS5A/$",'86&#^E7?$
M-QJE_P"*H8]&M4NCI:[W21@%WN.^2,X&,<^M`'0KK1G\.+JUG:O<LT886Z'+
M$YP5R`>ASV[5@)XXU&2>2!/#-TTT6"\8=BR9Z9&SBI?!,UW8W5YHVHP+;S`_
M:8HE8$!6/(7!/`.._>K>D?\`(\Z__N0?^@"@!FJ>*[NSU22QM=$GO6C178Q.
M<C<,\@*<5IZ#JEUJMO+)=Z9-I[(VT)+G+#'7E17'^(WC3QA>^;K<VD@Q1X>)
M';S..AVD5T?@V>&2QGCBUF75667<TLJ.I7(&%^8GT)_&@!NM^*+G3=7_`+/M
M-(EOY/*$I\ISD`G'0*?S]ZET7Q+_`&G+<6]S836-W!'YIAE[KZC(!].W>L;6
M].NM3\<M!9ZA+82K8!_,CSDC=C;P1QS^E/\`"<*V]SJ<.HR32:U'&5D::3?N
MC[%"><=/TH`6W\;ZE=0K-;^&+J:)NCQNS*?Q"5NQ:T[7^FVDMFT4E[;F9@S<
MQ$#)4C'/Z5YSI$L"Z=$'\6W6GMSFVCBE94Y/=3CGK^-=7J6K6-IK^AZA/=$V
MIM7Q,48[L@8.,9YH`Z36=0_LK2KB^\KS?)7.S=MSR!UP?6N?MO%NJSS1*?"]
MXB2,!YF6P`>_W*=KVNZ;K'A?5%T^Y\XQQJ7&QEQEACJ!7/Z9=6D5S:._C2\<
M(Z$P&&;#8(^7KC':@#MO$6MC0[%)Q;M<RR.$2)3@L>I['L*G@U:VET1=5)*6
MYA\YNY48R1]1TKE=<N=4O_%H_L:TBO/[+3#+*P"AW!R>6&>./P-)X;N7L-/U
M;1]8LGS`AG^S1X8F)A\P7GD#/KWH`N1>."9(Y+G1KRWL)"`MVP.WGH3QC'T)
MJSK?BBYTW5_[/M-(EOW\H2GRG.0"<=`I_/WKE3JMOID:R^'_`!!<O]W;I]Q"
MSCK]T'&!QQQ^=6O%$B_\):CSZK+I&ZR7,L:.QSN^[A2#_P#JH`ZS0-8O-5,_
MVS2)].\K;M\W/SYSG&5'3'ZULUS/@RYMY(KF&+7)M6=6#%I8W4H#QCYB?2NF
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`(H+>&
MVC\NWACB3).V-0HR>IP*6:"*XB,4\22QMU5U#`_@:DHH`AMK6WM(_+M8(H$_
MNQH%'Y"E@MH+8.((8X@[%VV*%W,>I..I]ZEHH`A@M;>V,AMX(HC(VYRB!=Q]
M3CJ:#;6YE>4P1>9(NQWV#++Z$]Q4U%`%<6-H%A46L`6`YB`C&(S_`+/I^%(]
MA9R),CVD#+.0TJF,$2$="WK^-6:*`(?LMN+A;@01><J;!)L&X+Z9ZX]JB;2]
M/:V6V:QM3;JVY8C"NT'U`QC/)JW10!2AT?3+>598-.M(I%.5=(%!'T(%(=&T
MMI3*VFV9D+;BY@7)/KG'6KU%`$4UO!/&(YH8Y$4@A74$`CH<&B*V@@DDDA@C
MC>4[I&1`"Y]2>]2T4`0FVMS<BY,$1N%7:)2@W@>F>N*5+>".>2=(8UFEP'D"
M@,^.F3WJ6B@"G<:5IUU*9;FPM9I#P7DA5B?Q(J2UL;2R#"TM8+<-RPBC"9^N
M*L44`1?9H!<_:?)C\\KL\W:-VWTSUQ[4C6ELUS]H:WB,^W9YI0;MOIGKBIJ*
M`,_^PM'_`.@58_\`@.G^%22Z5ITZ1I-86LBQ+MC5X5(0>@XX%7**`*<>DZ;%
M')''I]HB2@"15A4!P/48YJ,:'I"D$:58@CD$6Z?X5H44`0PVUO;M(T$$<1D;
M>Y1`NYO4XZFE^S0?:?M/D1_:-NSS=@W;?3/7%2T4`54TVQCN#<1V5LDYZR+$
MH;\\9I+G3-/O)?-NK&VGDQC=+$K''IDBK=%`%:UT^RLBQM+2WMR_WC%&$S]<
M"K-%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`456O;Z"R3=,^">BCJ?I5'[3J=X,VL"P(>C2GD_AB
MG8AS2=C7HK+T>]N+B2ZM[H*9+=@I9>C9S_A6I0U8<9*2N@HHHI%!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4UW5%+,<`4ZD(!&",BD[VT`9'-'
M+]QP3Z9I7D1/ONJ_4XK+N"89PZG&#[5?E2.:$-(!]WBN2GB)3YHV]Y%-6)//
MA_YZI_WT*J7D]W(1%8JAS]Z4MG;^%9H'SX]ZVRB6\3LBXP,UGA<7.M=M))!.
M&EKF?::?:V,AFGE\VX/5F/3Z5;O+Q+>U\U?F9N$4=6-5+3,DV]N23[5<^S`S
M^?+R$'R+V7WK?#5Y5[S>Q$H*"M$BTFS:TMB93F:4[Y#[FK]9<.O6$S.HEQL&
M22#3(/$>GSW`A60@L<`D'!KK:9G&<$DDS6J"2\AC."^2/2G7+E+9W4]N*R[*
M%;B4B0]L_6O/Q.(G"<:=-:ON;Q2:NS3BNX93A6Y]#4QX%9<UC(DP,`)'UZ5I
M1[O*&_KCFKP]6K)N-2-FON!I=""*]62?R@A!SC.:M53B>U-P0@_>9/K4=]K%
MI82B.X<JQ&1P36F'<I1?-)/T)FU'5Z&A1433QK;F<G]V%W9]JJV&K6NH2,EN
MQ8J,G@BM[$\R3M<IR^(XHM1-F8&+!]F[=[UM5@S3Z*-3*R1_Z3OP3\WWLUN2
M2+%&TCG"J,D^@JF13;=[NXZL]-:L7N_LRRGS=Q7&#UJ!/$FG22^5YI&>`Q!Q
M7,V9#>*`0<@SL0?Q--1[F=2O9KEU.^HJ.::.")I)6"HHR2:R&\4:<'P'8CU"
MU*39M*<8[LVZ*KV=Y!>P^;;N'7^56*12:>J"BBB@84444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1136944LQ`4#))[4`9E^
MN&;@=?2HQ!<WDT;-)LM8ER`IY<X[TZUN)-5DE=(PENORHY'+'_"I1;74"L$8
M%:\UPGAZTI*-TUT'>-2***_ZW\:V+U@MJ^>XQ6,,[^.N:OO;74Q'FL`!7#@Y
MR4)QC%MLUENA+!,LG`_*M&3_`%;?0U'!`(E[%O6I)/\`5M]#7KX6DZ5-19E)
MW.`T2VCN]7$4P)3DD>M6/$]A%87D36P"*RYP.QR:;X:_Y#H^AJYXU(^T0+GG
M9G'XFN^_O'EJ*]BWYG1Z>?M&EP[^=R`&J,T$MK)N4G'9A5K3I1#H\#D$@)4]
MM=K<EEQC'8GK7EXJG2JS4&[2Z'J4VU%,@M=0W$)*.3_%5\_=/TK(U&%(I04_
MBZCTK1M26M$)ZXJ,+5J<\J-35KJ5)+=&?:?\A`_4_P`ZSO&EOF*WG`^Z2#^F
M*T;3_D('ZG^=2Z_;?:M)F4=5&\?@*K+7:#]3+$QYH-&5<7Y_X1)6!^=QL_7_
M``I_@VWV6DLY'+G`^G^17+_:7:R%IV$A8?D!_2O0-(@^SZ9;Q^BY_/G^M>G+
M1''1?M)I]D<=>?\`(SO_`-=S_.NB\53-%I#!"1O(!QZ5SMY_R,[_`/7<_P`Z
MW_%P_P")2/\`>'\Q3>Z%#X*AG^&=*MKRRFEN(PYW;1GMQ6;I\8A\2)&OW4F*
MCZ`FM_P>0=,E'<.?Y5AVO_(T_P#;PW\S3OJR7%*,&CIM>TZYU**.."5409W`
MD\],5FRZ'8V.DR"Z=?M&TD-GOVQ5OQ+J\EA&L,&/,D!RW]T5FP:`9=/DOKZ5
MC)L+!?P[U*O8UJ<KF[*[%\%NWVF>/)V[,X]\BNOKCO!?_'[/_P!<S_,5V-*>
MYIAOX:"BBBH.@****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@!*P]0EEU.^_L^V;;"G^O<?R_G6U*V(SCJ1Q]:SM!M6@LVDE'[
M^5MTA/7/^336FIG-.3430@A2")8HE"JHX`IS_<;Z4R>XBMXS),X11W-97]I3
MZB66Q0I"/O3,.OT%)K1LIR4="L9`LH4#<Y/"CO6_%YA&9,`^@[5BQVQA_P!7
M&S-W=NIK8@F,N<H5QZUYF!Y*;<%>[-)<SU9-39/]6WT-.IKC*,!Z5Z9)Y[I4
M,\VIE;63RYADJ:ORZ/J^H7ZF\7@8!<E<`?A4^A:3>VNKB::$JF#S775K*5GH
M<-*AS1]ZY#'`B6JP=550M9\EE/%(6AY'8@UK45Q5\-"O9RW74[XOEV,E+*>:
M3,O`[DFM-4"1A5Z`4^BE0PT*-^7=C<FS.M[65+PR,N%R><U?=0Z%6Z$8-.HJ
MZ-&-%-1$W<XF+PW?#4$9HOW(D!)W#IGZUVBJ%4*.@&*=170Y-F-.E&G>QR5S
MHM])KK7*PYB,I;.X=,_6N@U6R%_I\D'\1&5^O:KM%#DV$:48IKN<9I^FZW:2
M/#"/*1S\S94CZU)::#>V^LQS%-\:ODN6'/O77T4^=D+#15M7H<[XGTBXOFCF
MMEWLH(9<@52AL-=N;4V\SF.$`\$KS[<5U]%)2=K#E0BY.5]SF_#.E7>GW<KW
M,>U63`.X'G(KI***3=]32$%"/*@HHHI%A1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`4=6M9[JV46TFR6-PZGUX(Q^M4`GB"
M4!7>"(?WEY/\ZW:*:9G*FF[W,>#08C();Z5[J0?W^GY5K(JHH50`HZ`4ZBAN
MY48*.P4444B@HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
0*`"BBB@`HHHH`****`/_V3\_
`
end

</TEXT>
</DOCUMENT>
</SUBMISSION>
